ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Safety and Efficacy of Prophylactic Valganciclovir Dosing after Solid Organ Transplant

K. Gandhi, D. Masic, M. Santarossa, F. Albarillo, N. Clark, G. Reid

Loyola University Medical Center, Maywood, IL

Meeting: 2020 American Transplant Congress

Abstract number: A-188

Keywords: Cytomeglovirus, Heart/lung transplantation, Lung transplantation, Neutropenia

Session Information

Date: Saturday, May 30, 2020

Session Name: Poster Session A: All Infections (Excluding Kidney & Viral Hepatitis)

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

Related Abstracts
  • Evaluation of the Safety and Efficacy of Valganciclovir to Prevent Cytomegalovirus Infection in Pediatric Solid Organ Transplant Recipients Utilizing Two Dosing Regimens
  • A National Survey of Valganciclovir Dosing Strategies in Pediatric Solid Organ Transplant Recipients

*Purpose: At centers where antiviral prophylaxis is used after solid organ transplant, valganciclovir is administered for the prevention of cytomegalovirus (CMV). At Loyola University Medical Center (LUMC), most thoracic transplant recipients receive valganciclovir 450 mg twice daily (BID), while most abdominal transplant recipients receive 900 mg daily (QD) for CMV prophylaxis in patients with creatinine clearance (CrCl) greater than 60 mL/min. The purpose of this study is to analyze the safety and efficacy of two different prophylactic valganciclovir dosing strategies after solid organ transplant.

*Methods: This was a retrospective study of heart, lung, and liver transplant recipients who received valganciclovir for CMV prophylaxis from August 2014 to August 2019. Patients were excluded if CrCl was less than 60 mL/min. The primary endpoint was incidence of neutropenia. The secondary endpoint was incidence of CMV infection, which was defined as having a detectable serum CMV viral load. Patient follow-up occurred within the study period.

*Results: Eighty patients were included in the analysis, with 40 patients receiving valganciclovir 900 mg QD and 40 patients receiving 450 mg BID. Baseline characteristics were similar, except there was a significantly lower baseline WBC in the 900 mg QD group (Table 1). There were no significant differences in post-transplant lab results or incidence of acute rejection (suspected and/or confirmed). The incidence of CMV infection was more prevalent in the 450 mg BID group, and the 450 BID group also had a longer time to undetectable CMV viral load (Table 1). There was no significant difference in the incidence or severity of neutropenia post-transplant between both prophylactic dosing strategies.

 border=

*Conclusions: Both 450 mg BID and 900 mg QD dosing strategies of prophylactic valganciclovir appear to be safe and effective. Differences in incidence of CMV infection and time to viral clearance were found between the two groups in this study. However, a major limitation is that the majority of patients in 450 mg BID group were thoracic transplant recipients and majority of patients in the 900 mg QD group were liver transplant recipients. Since inherent differences exist between these two groups with regards to incidence and severity of CMV infection and disease, more research is warranted.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Gandhi K, Masic D, Santarossa M, Albarillo F, Clark N, Reid G. Safety and Efficacy of Prophylactic Valganciclovir Dosing after Solid Organ Transplant [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/safety-and-efficacy-of-prophylactic-valganciclovir-dosing-after-solid-organ-transplant/. Accessed March 4, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.